12:00 AM
 | 
Oct 12, 2009
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Allos sales and marketing update

Allos launched Folotyn pralatrexate in the U.S. to treat relapsed or refractory peripheral T cell lymphoma (PTCL)....

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >